Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Ethical challenges in paediatric clinical trials in multiple sclerosis.

Tenembaum SN.

Ther Adv Neurol Disord. 2012 May;5(3):139-46. doi: 10.1177/1756285612437360.

2.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
3.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
4.

Alemtuzumab for multiple sclerosis.

Riera R, Porfírio GJ, Torloni MR.

Cochrane Database Syst Rev. 2016 Apr 15;4:CD011203. doi: 10.1002/14651858.CD011203.pub2. Review.

PMID:
27082500
5.

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.

Cochrane Database Syst Rev. 2013 Jun 6;(6):CD008933. doi: 10.1002/14651858.CD008933.pub2. Review.

PMID:
23744561
6.

Teriflunomide for multiple sclerosis.

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD009882.

PMID:
23235682
7.

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

English C, Aloi JJ.

Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4. Review.

PMID:
25846320
8.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
9.

Therapy of multiple sclerosis in children and adolescents.

Tenembaum SN.

Clin Neurol Neurosurg. 2010 Sep;112(7):633-40. doi: 10.1016/j.clineuro.2010.04.015. Epub 2010 May 14. Review.

PMID:
20471159
10.

Interferon-β-1b: a review of its use in multiple sclerosis.

Plosker GL.

CNS Drugs. 2011 Jan;25(1):67-88. doi: 10.2165/11206430-000000000-00000. Review.

PMID:
21128695
11.

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K.

J Manag Care Pharm. 2007 Apr;13(3):245-61.

12.

Dimethyl fumarate for multiple sclerosis.

Xu Z, Zhang F, Sun F, Gu K, Dong S, He D.

Cochrane Database Syst Rev. 2015 Apr 22;(4):CD011076. doi: 10.1002/14651858.CD011076.pub2. Review.

PMID:
25900414
13.
14.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
15.

Therapeutic strategies in childhood multiple sclerosis.

Ghezzi A.

Ther Adv Neurol Disord. 2010 Jul;3(4):217-28. doi: 10.1177/1756285610371251.

16.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Review.

PMID:
24310855
17.

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

Cochrane Database Syst Rev. 2016 Nov 24;11:CD009333. Review.

PMID:
27880972
18.

Pharmacological treatment for memory disorder in multiple sclerosis.

He D, Zhang Y, Dong S, Wang D, Gao X, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 17;(12):CD008876. doi: 10.1002/14651858.CD008876.pub3. Review.

PMID:
24343792
19.

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.

Supplemental Content

Support Center